Skip to content

Study · Not a test of the peptide alone · 2008

7 results

Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease.

Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology10 Oct 2007Cited by 46 (Europe PMC)

PMID17928813 (opens in a new tab)DOI10.1038/sj.npp.1301591 (opens in a new tab)PepBankPUB-17928813
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of Humanin aloneAnimal study (in vivo)Pharmacokinetics

    Intranasally given Colivelin, a Humanin derivative, was transferred to the central nervous system via the olfactory bulb.

    In plain wordsIn animals, a Humanin-based peptide given through the nose reached the brain through the olfactory bulb.

    Peptide
    Humanin
    Outcome
    Not applicableDelivery of intranasal Colivelin to the central nervous system
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Nervous system and cognition

    Source sentences

    Summary
    In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 02AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    Intranasal Colivelin, a Humanin derivative, reduced memory impairment in Alzheimer's disease models in a dose-responsive manner.

    In plain wordsIn animal models of Alzheimer's disease, a Humanin-based peptide given through the nose eased memory problems, with larger doses working better.

    Peptide
    Humanin
    Outcome
    DecreaseMemory impairment in Alzheimer's disease models
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    Memory benefit of Humanin derivatives such as Colivelin appeared correlated with higher STAT3 phosphorylation in the septohippocampal region.

    In plain wordsIn animal models, the memory benefit of a Humanin-based peptide was linked to higher STAT3 activity in a memory-related brain area.

    Peptide
    Humanin
    Outcome
    IncreaseSTAT3 phosphorylation in the septohippocampal region
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  4. 04AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    Colivelin treatment inhibited the amyloid-beta induced decrease in the number of choline acetyltransferase-positive neurons in the medial septum.

    In plain wordsIn animal models, a Humanin-based peptide prevented the loss of acetylcholine-making nerve cells caused by amyloid-beta.

    Peptide
    Humanin
    Outcome
    IncreaseCholine acetyltransferase-positive neurons in the medial septum
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    We further demonstrate that CLN treatment inhibits an Abeta induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  5. 05AnimalNot a test of Colivelin aloneAnimal study (in vivo)Pharmacokinetics

    In AD models, intranasal CLN reached the CNS via the olfactory bulb.

    In plain wordsIn animal tests, nasal CLN reached the central nervous system through the olfactory bulb.

    Peptide
    Colivelin
    Outcome
    Not applicableTransfer to the CNS
    Study

    n: not reported in source

    AD models
    Outcome group
    Pharmacokinetics · Nervous system and cognition

    Source sentences

    Summary
    In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  6. 06AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In AD models, intranasal CLN ameliorated memory impairment in a dose-responsive manner.

    In plain wordsIn animal AD models, nasal CLN reduced memory impairment in a dose-responsive manner.

    Peptide
    Colivelin
    Outcome
    DecreaseMemory impairment
    Study

    n: not reported in source

    AD models
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

  7. 07AnimalNot a test of Colivelin aloneAnimal study (in vivo)Efficacy outcome

    In AD models, CLN inhibited an Abeta-induced decrease in medial septal ChAT-positive neuron numbers.

    In plain wordsIn animal tests, CLN inhibited an Abeta-induced decrease in ChAT-positive neuron numbers in the medial septum.

    Peptide
    Colivelin
    Outcome
    IncreaseChAT-positive neurons in medial septum
    Study

    n: not reported in source

    AD models
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    We further demonstrate that CLN treatment inhibits an Abeta induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum.

    In this study, Colivelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Colivelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.